Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

143 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Baseline and early functional immune response is associated with subsequent clinical outcomes of PD-1 inhibition therapy in metastatic melanoma patients.
Gérard A, Doyen J, Cremoni M, Bailly L, Zorzi K, Ruetsch-Chelli C, Brglez V, Picard-Gauci A, Troin L, Esnault VLM, Passeron T, Montaudié H, Seitz-Polski B. Gérard A, et al. Among authors: doyen j. J Immunother Cancer. 2021 Jun;9(6):e002512. doi: 10.1136/jitc-2021-002512. J Immunother Cancer. 2021. PMID: 34088741 Free PMC article. Clinical Trial.
Proton versus photon therapy for esophageal cancer - A trimodality strategy (PROTECT) NCT050555648: A multicenter international randomized phase III study of neoadjuvant proton versus photon chemoradiotherapy in locally advanced esophageal cancer.
Mortensen HR, Populaire P, Hoffmann L, Moeller DS, Appelt A, Nafteux P, Muijs CT, Grau C, Hawkins MA, Troost EGC, Defraene G, Canters R, Clarke CS, Weber DC, Korevaar EW, Haustermans K, Nordsmark M, Gebski V, Achiam MP, Markar SR, Radhakrishna G, Berbee M, Scartoni D, Orlandi E, Doyen J, Gregoire V, Crehange G, Langendijk J, Lorgelly P, Blommenstein HM, Byskov CS, Ehmsen ML, Jensen MF, Freixas GV, Bütof R; PROTECT consortium. Mortensen HR, et al. Among authors: doyen j. Radiother Oncol. 2024 Jan;190:109980. doi: 10.1016/j.radonc.2023.109980. Epub 2023 Nov 5. Radiother Oncol. 2024. PMID: 37935284 Free article. No abstract available.
[Indications and results for protontherapy in cancer treatments].
Doyen J, Bondiau PY, Benezery K, Thariat J, Vidal M, Gérard A, Hérault J, Carrie C, Hannoun-Lévi JM. Doyen J, et al. Cancer Radiother. 2016 Oct;20(6-7):513-8. doi: 10.1016/j.canrad.2016.06.005. Epub 2016 Sep 7. Cancer Radiother. 2016. PMID: 27614508 Review. French.
Occurrence and number of immune-related adverse events are independently associated with survival in advanced non-small-cell lung cancer treated by nivolumab.
Bouhlel L, Doyen J, Chamorey E, Poudenx M, Ilie M, Gal J, Guigay J, Benzaquen J, Marquette CH, Berthet JP, Mouroux J, Schiappa R, Padovani B, Hofman P, Otto J. Bouhlel L, et al. Among authors: doyen j. Bull Cancer. 2020 Sep;107(9):946-958. doi: 10.1016/j.bulcan.2020.04.019. Epub 2020 Jul 6. Bull Cancer. 2020. PMID: 32646604
Impact of radiotherapy schedule on survival of patients treated with immune-checkpoint inhibitors for advanced melanoma and non-small cell lung cancer.
Sumodhee S, Guo L, Bouhlel L, Picard A, Otto J, Naghavi AO, Richier Q, Lévy A, Bondiau PY, Poudenx M, Passeron T, Lacour JP, Montaudié H, Doyen J. Sumodhee S, et al. Among authors: doyen j. Cancer Radiother. 2022 Nov;26(8):1045-1053. doi: 10.1016/j.canrad.2022.04.005. Epub 2022 Aug 1. Cancer Radiother. 2022. PMID: 35927166
[Role of immunotherapy in locally advanced non-small cell lung cancer].
Levy A, Doyen J, Botticella A, Bourdais R, Achkar S, Giraud P, Du C, Naltet C, Lavaud P, Besse B, Pradère P, Mercier O, Caramella C, Planchard D, Deutsch E, Le Péchoux C. Levy A, et al. Among authors: doyen j. Cancer Radiother. 2020 Feb;24(1):67-72. doi: 10.1016/j.canrad.2019.09.007. Epub 2020 Feb 6. Cancer Radiother. 2020. PMID: 32037126 French.
143 results